Get the Stockscreener App
0.1485
1.71%
0.0025
After Hours:
.15
0.0015
+1.01%
Tonix Pharmaceuticals Holding Corp stock is traded at $0.1485, with a volume of 19.23M.
It is up +1.71% in the last 24 hours and down -35.15% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$0.146
Open:
$0.1454
24h Volume:
19.23M
Relative Volume:
0.81
Market Cap:
$15.31M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-0.00795
EPS:
-18.6875
Net Cash Flow:
$-114.09M
1W Performance:
+10.08%
1M Performance:
-35.15%
6M Performance:
-97.51%
1Y Performance:
-99.15%
1-Day Range:
$0.138
$0.153
1-Week Range:
$0.13
$0.2124
52-Week Range:
$0.13
$22.14
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Disea - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
Tonix secures patent for migraine treatment into 2036 By Investing.com - Investing.com Canada
What's Going On With Tonix Pharmaceuticals Stock Friday? - Benzinga
Tonix Pharma Secures Patent, Bolsters Migraine Treatment Future - TipRanks
Tonix secures patent for migraine treatment into 2036 - Investing.com
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines - StockTitan
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines - Wall Street Reporter
Tonix Pharm stock plunges to 52-week low of $0.13 By Investing.com - Investing.com Australia
Tonix Pharm stock plunges to 52-week low of $0.13 - Investing.com
Tonix Pharm stock plunges to 52-week low of $0.13 By Investing.com - Investing.com Canada
Tonix Pharmaceuticals advances fibromyalgia treatment - Investing.com
Technical analysis of Tonix Pharmaceuticals Holding Corp (TNXP) stock chart patterns - US Post News
Tonix Pharma Highlights TNX-102 SL at Global Pharmaceutics Conference - TipRanks
Balance Sheet Insights: Tonix Pharmaceuticals Holding Corp (TNXP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Tonix Pharmaceuticals announces data presentations on TNX-102 SL - TipRanks
Tonix Pharmaceuticals advances fibromyalgia treatment By Investing.com - Investing.com UK
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) - StockTitan
Tonix Pharmaceuticals advances fibromyalgia treatment By Investing.com - Investing.com Australia
Why Tenon Medical (TNON) Stock Is Skyrocketing Friday - Benzinga
Tonix secures patent for migraine nasal spray Tosymra By Investing.com - Investing.com Canada
Tonix secures patent for migraine nasal spray Tosymra - Investing.com
Tonix Pharma Secures Patent, Eyes Migraine Market Growth - TipRanks
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines - Yahoo Finance
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines - StockTitan
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solutio - PharmiWeb.com
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution - AccessWire
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution - Yahoo Finance
Tonix vaccine aligns with WHO mpox criteria - Investing.com India
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency - StockTitan
Tonix vaccine aligns with WHO mpox criteria - Investing.com
Tonix vaccine aligns with WHO mpox criteria By Investing.com - Investing.com Australia
Tonix questions efficacy of oral migraine drugs in awareness campaign - FiercePharma
Tonix Sees Mpox Vaccine Opportunity As A Potential Lifeline - Scrip
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharma Bolsters Leadership and Updates Drug Timeline - TipRanks
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations - StockTitan
TNXP: Mpox Declared a Public Health Emergency of International Concern by World Health Organization - Research Tree
Tonix reports promising mpox vaccine preclinical data By Investing.com - Investing.com Canada
What's Going On With Tonix Pharmaceuticals (TNXP) Stock? - Benzinga
Tonix reports promising mpox vaccine preclinical data By Investing.com - Investing.com Australia
Tonix reports promising mpox vaccine preclinical data - Investing.com
Tonix reports promising mpox vaccine preclinical data By Investing.com - Investing.com UK
Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta - StockTitan
Tonix Pharmaceuticals announces $10 milion stock buyback - Investing.com India
Tonix Pharmaceuticals announces $10 milion stock buyback - Investing.com
Tonix Pharmaceuticals announces $10 milion stock buyback By Investing.com - Investing.com Australia
Tonix Pharmaceuticals announces $10 milion stock buyback By Investing.com - Investing.com UK
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek - StockTitan
Tonix Pharmaceuticals Holding Corp. announces an Equity Buyback for $10 million worth of its shares. - Marketscreener.com
Tonix Pharm stock hits 52-week low at $0.15 amid steep decline - Investing.com India
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):